Program Agenda. Advances in Peanut Allergy Immunotherapy: When Science Meets Technology.

Slides:

Advertisements

Similar presentations

Areas of Research Specific issues. Clinical Trials Phase I First use in humans of an experimental drug or treatment In a small group of healthy volunteers.

Advertisements

Food Allergy Update Thomas Flaim, M.D.. Prevalence of Food Allergy Prevalence rate is 6% in children < 3 years of age; 4% in adults Prevalence rate is.

Common Food Sensitivities, Allergens, and Intolerances

SOA/OS Advanced Operating Systems 1 Project Title Team Name day month year Project Title Abbreviation, Team Name.

BCG complications.

Three Traps to Avoid & Bioinformatics Advantage 1.) In the Discovery Phase Its ok to “Fish” for significant relationships in your data (i.e. look at.

SLIT: dealing with trouble, doing it right. Giovanni B Pajno MD Professor of Pediatrics Department of Pediatrics – Allergy Unit University of Messina Italy.

Greg Rex Department of Pediatrics, Division of Allergy IWK Health Centre Immunology and Allergy Update.

Harvey Luksenburg, Ph.D. National Heart, Lung, & Blood Institute two years of the initial event. The NIH’s Role in the Prevention and Reduction of Strokes.

BTEC LEVEL 3 SUBSIDIARY DIPLOMA CHILDREN’S CARE, LEARNING AND DEVELOPMENT 1 ‘A’ LEVEL.

Catherine M. Bettcher, M.D. CME Director & Assistant Professor, Department of Family Medicine, University of Michigan No Nuts Allowed: Food Allergies in.

Introduction. Adult ADHD in the Real World: From Clinical Trials to Clinical Practice.

Sublingual immunotherapy in allergic conjuctivitis with house dust and dust mite allergies DR VIPUL SHAH.

BABY-FRIENDLY HOSPITAL INITIATIVE Revised,Updated and Expanded for Integrated Care “Maternity”, 1963, © 2003 Estate of Pablo Picasso/Artists Rights Society.

Figure 1) General paediatrician and dietitian recommendations regarding maternal avoidance of allergic foods during breastfeeding From: Early nutrition.

Oral immunotherapy and omalizumab for food allergy

Food Allergies: Diagnosis & Management

New Horizons for SMA.

Evolving Paradigms in Recurrent/Metastatic SCCHN

Burden of Atrial Fibrillation The Percentage of Strokes Attributable to AF Increases With Age.

Evolution of Treatment Strategies Targeting IL-23 for Psoriasis

IL-12 and IL-23.

Why New Treatments for Schizophrenia Should Be on Your Radar

Clinical Considerations in the Management of EGFR-Mutated Advanced NSCLC.

NOACs In Long-term VTE Treatment: A State Of The Art Review

Omega-3 Prescriptions vs Supplements in Practice

The Clinical Enigma of Cardiogenic Shock

Progression After Cancer Immunotherapy in Advanced NSCLC

Learning Objectives. A Multidisciplinary Approach in Advanced NSCLC in the Era of Immuno-Oncology.

The Nurse View: Overcoming Challenges Associated With Cancer Immunotherapy.

Surveying the Safety of NOACs in the Real World

The Parkinson's Disease Psychosis Journal Club

DENGUE VACCINE.

Is RA Treatment Addressing the Real Needs of Patients?

Advances in Peanut Allergen Immunotherapy

Atopic Dermatitis. Introduction to a Clinical Course On New Developments In Atopic Dermatitis.

Quantitative Assessment of the Safety Benefits Associated with Increasing Clinical Peanut Thresholds Through Immunotherapy Joseph L. Baumert, PhD, Steve.

Essential Concepts in the Use of Immunotherapies in Bladder Cancer

Immunotherapy for cSCC

Chapter 8 Safety Management

Advancing Care in Genitourinary Cancer: Perspectives From Chicago

Personalized Therapy in Relapsed or Refractory CLL

In-Depth Discussion of Key Data on Immunotherapy for Allergic Diseases

Advances in Peanut Allergy

Advances in Immunotherapy for Peanut Allergy

Immune Checkpoint Inhibitors in Lung Cancer

Treatment-Resistant Schizophrenia

Understanding the feasibility and implications of implementing early peanut introduction for prevention of peanut allergy Jennifer J. Koplin, PhD, Rachel.

Peanut Allergy.

Biomarker Testing: Harnessing All Sides of the Tumor Microenvironment

Management of Risk Factors to Decrease Peanut Allergy Occurrences

Peanut Allergy Immunotherapy

Assessing the Burden of Hyperkalemia

Reduced risk of peanut sensitization following exposure through breast-feeding and early peanut introduction Tracy J. Pitt, MD, Allan B. Becker, MD,

Identifying infants at high risk of peanut allergy: The Learning Early About Peanut Allergy (LEAP) screening study George Du Toit, MBBCh, FRCPCH, Graham.

Peanut Allergy Immunotherapy

Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition

Optimizing Outcomes for Patients With Systemic Lupus Erythematosus: Key Considerations.

Assessing the Burden of Hyperkalemia

Peanut Allergy Immunotherapy

Case Studies in Peanut Allergy Immunotherapy

Evaluating the Science of Cardiogenic Shock

Current Status of Biomarkers for Immune Checkpoint Inhibitors

Clinical Comparisons.

Update on risk factors for food allergy

Probiotic supplementation for the first 6 months of life fails to reduce the risk of atopic dermatitis and increases the risk of allergen sensitization.

Treatment Advances for RA

The Real Burden of Rosacea

MenB Update: Communicating the Imperative With Parents

Glucose levels must be monitored in patients receiving steroids for immunotherapy-related toxicity Title: Subtitle Risk Assessment of Hyperglycaemia Induced.

Presentation transcript:

Advances in Peanut Allergy Immunotherapy: When Science Meets Technology

Program Agenda

Welcome and Introductions

Peanut Allergy Prevalence and Natural Course

The Burden of Accidental Exposures

Immunotherapy Strategies Aim to Balance Efficacy, Safety, and Practicality

The Care Team

Pathophysiology of Peanut Allergy

The Skin as an Immune Organ Early Peanut Allergen Exposure

LEAP-On Prevalence of Peanut Allergy 12 Months After Avoidance

Recommendations for Risk Reduction of Peanut Allergy in Infants

Goals for Minimized Risk to Unintentional Peanut Exposure

Modeling of Risk Assessment

What Is the Clinical Relevance of a Higher Threshold?

Allergen Immunotherapy: Review of Phase 3 Data

Peanut Allergen Immunotherapy*

PALISADE Phase 3 Trial

PALISADE Safety Data

ARC003 Discontinuations in AR101 Group

Phase 3 PEPITES Study (Children 4 to 11 Years of Age) Results

Phase 3 PEPITES Study (Children 4 to 11 Years of Age) Preliminary Results

REAL Life Use and Safety of EPIT (REALISE) Study Design and Preliminary Results[a,b]

Advantages and Disadvantages of Peanut Allergy Immunotherapy

From Bench to Bedside: Case-Based Discussion

Case 1 Noah

Considerations for Managing Peanut Allergy in a Young Child

Case 2 Ben

Managing Peanut Allergy in a Preschooler

Case 3 Sabrina

Developing a Long-Term Management Strategy

Conclusions

Abbreviations